News | October 12, 2022
Merck recognized on Fortune’s 2022 change the World List
This recognition marks the third time in five years that Merck has been included on Fortune’s Change the World list.
This recognition marks the third time in five years that Merck has been included on Fortune’s Change the World list.
Theruptor Novo is a best in class patented product which provides an optimum healing environment and addresses the concerns of chronic wound dressing
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
One in two women with advanced ovarian cancer has an HRD-positive tumor
Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir
_256_384.jpg){kind=logo}
Veda Corporate Advisors was the exclusive financial advisor to SHPL and its shareholders.
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
Subscribe To Our Newsletter & Stay Updated
